This week Mike and Laura turn to health and life sciences, a sector experiencing one of its most consequential stretches in years. Frontier AI labs are moving directly into drug discovery, AI designed drug candidates are heading into pivotal trials, and regulators on both sides of the Atlantic are finally moving in lockstep. Here is what C suite leaders in regulated industries need to know.
First, the headline story: on June 30, 2026, Anthropic launched Claude Science, a research platform built for scientific laboratories and pharmaceutical research operations, and announced an internal drug discovery program focused on neglected diseases. The move places Anthropic alongside Google DeepMind and OpenAI in the race to bring frontier AI into pharma, and the market reaction was immediate, with established computational drug discovery firms seeing shares fall on the news.
Second, 2026 is the year AI drug discovery meets clinical reality. Industry estimates suggest 15 to 20 AI programs may enter pivotal Phase three trials this year, backed by enormous capital including Isomorphic Labs raising 2.1 billion dollars and Eli Lilly committing 2.75 billion dollars to expand its Insilico Medicine partnership. Yet no AI designed drug has received FDA approval to date, making the coming trial readouts the true test of the technology.
Finally, the hosts examine the operational transformation underway, with research showing 75 to 85 percent of pharma workflows contain tasks that agentic AI could enhance, potentially freeing 25 to 40 percent of organizational capacity, alongside surging investment across cell and gene therapies and the broader AI in life sciences market.
To learn more about how PiTech Solutions helps regulated businesses bring technology strategy and governance discipline together, visit pitechsol.com.